415 related articles for article (PubMed ID: 15342842)
21. Twenty-four-hour esophageal impedance-pH monitoring in healthy preterm neonates: rate and characteristics of acid, weakly acidic, and weakly alkaline gastroesophageal reflux.
López-Alonso M; Moya MJ; Cabo JA; Ribas J; del Carmen Macías M; Silny J; Sifrim D
Pediatrics; 2006 Aug; 118(2):e299-308. PubMed ID: 16831894
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
23. Experience with intravenous enoxaparin in critically ill infants and children.
Crary SE; Van Orden H; Journeycake JM
Pediatr Crit Care Med; 2008 Nov; 9(6):647-9. PubMed ID: 18838932
[TBL] [Abstract][Full Text] [Related]
24. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
[TBL] [Abstract][Full Text] [Related]
26. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
Hicks JK; Shelton CM; Sahni JK; Christensen ML
Ann Pharmacother; 2012; 46(7-8):943-51. PubMed ID: 22828970
[TBL] [Abstract][Full Text] [Related]
27. [Therapeutic indications for acute venous thromboembolism. Current status and future perspectives].
Prandoni P; Simioni P; Pagnan A
Minerva Cardioangiol; 2003 Aug; 51(4):361-71. PubMed ID: 12900718
[TBL] [Abstract][Full Text] [Related]
28. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A
Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132
[TBL] [Abstract][Full Text] [Related]
29. Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy.
Narin C; Reyhanoglu H; Tülek B; Onoglu R; Ege E; Sarigül A; Yeniterzi M; Durmaz I
Adv Ther; 2008 Jun; 25(6):585-94. PubMed ID: 18568442
[TBL] [Abstract][Full Text] [Related]
30. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
George-Phillips KL; Bungard TJ
Pharmacotherapy; 2006 Oct; 26(10):1479-90. PubMed ID: 16999658
[TBL] [Abstract][Full Text] [Related]
31. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
Kruse MW; Lee JJ
Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
[TBL] [Abstract][Full Text] [Related]
32. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels.
Gyamfi C; Cohen R; Desancho MT; Gaddipati S
J Matern Fetal Neonatal Med; 2005 Nov; 18(5):329-31. PubMed ID: 16390793
[TBL] [Abstract][Full Text] [Related]
34. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.
Noble SI; Hood K; Finlay IG
Palliat Med; 2007 Sep; 21(6):473-6. PubMed ID: 17846086
[TBL] [Abstract][Full Text] [Related]
35. Half-dose enoxaparin vs. full-dose enoxaparin for postoperative bridging therapy in patients after cardiac surgery: which dose regimen should be preferred?
Weiss A; Brose S; Ploetze K; Matschke K
Clin Hemorheol Microcirc; 2013 Jan; 54(3):249-58. PubMed ID: 23648452
[TBL] [Abstract][Full Text] [Related]
36. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
Omran H; Hammerstingl C; Paar WD;
Med Klin (Munich); 2007 Oct; 102(10):809-15. PubMed ID: 17928964
[TBL] [Abstract][Full Text] [Related]
37. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
38. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
[TBL] [Abstract][Full Text] [Related]
39. [Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice].
Heidenreich C; Hohmann V; Bramlage P
Med Klin (Munich); 2009 Jan; 104(1):20-7. PubMed ID: 19142593
[TBL] [Abstract][Full Text] [Related]
40. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.
Streif W; Goebel G; Chan AK; Massicotte MP
Arch Dis Child Fetal Neonatal Ed; 2003 Sep; 88(5):F365-70. PubMed ID: 12937038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
